Molecular monitoring of minimal residual disease in patients with multiple myeloma (Q35668677)

9 August 2017

1 reference

title

Molecular monitoring of minimal residual disease in patients with multiple myeloma (English)

1 reference

9 August 2017

Roland Fenk

1

1 reference

PubMed ID

14965865

9 August 2017

Rainer Haas

series ordinal

2

1 reference

PubMed ID

14965865

9 August 2017

Ralf Kronenwett

series ordinal

3

1 reference

9 August 2017

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

9

1 reference

9 August 2017

1

1 reference

9 August 2017

17-33

1 reference

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

9 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Randomized trial experience of the Intergroupe Francophone du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Minimal residual disease in chronic myeloid leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Minimal residual disease monitoring in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

An advantageous method to evaluate IgH rearrangement and its role in minimal residual disease detection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Comparison of ethidium bromide-stained agarose gel electrophoresis and automated fragment analysis for evaluation of IgH gene products

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Molecular methods for detection and quantification of myeloma cells after bone marrow transplantation: comparison between real-time quantitative and nested PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Somatic generation of antibody diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Development of the primary antibody repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Immunoglobulin heavy chain gene analysis in lymphomas: a multi-center study demonstrating the heterogeneity of performance of polymerase chain reaction assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Assessment of IgH PCR strategies in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Improved PCR method for detecting monoclonal immunoglobulin heavy chain rearrangement in B cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Incomplete DJH rearrangements of the IgH gene are frequent in multiple myeloma patients: immunobiological characteristics and clinical implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Real time quantitative PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Zwischenmolekulare Energiewanderung und Fluoreszenz

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Incomplete DJH rearrangements as a novel tumor target for minimal residual disease quantitation in multiple myeloma using real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Potential of LightCycler technology for quantification of minimal residual disease in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

A real-time PCR assay for the quantification of residual malignant cells in B cell chronic lymphatic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Rapid detection of herpes simplex virus and varicella-zoster virus infections by real-time PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Molecular assays for detection of human metapneumovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Rapid diagnosis of enterovirus infections by real-time PCR on the LightCycler using the TaqMan format

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Comparison of different approaches to quantify Staphylococcus aureus cells by real-time quantitative PCR and application of this technique for examination of cheese

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Sensitive and specific method for rapid identification of Streptococcus pneumoniae using real-time fluorescence PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Tumour kinetics in multiple myeloma before, during, and after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Clinical and biologic implications of recurrent genomic aberrations in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

High-dose therapy and immunomodulatory drugs in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Moving disease biology from the lab to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Cytokine mRNA quantification by real-time PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Impact of complete remission with intensive therapy in patients with responsive multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Selection and transplantation of autologous CD34+ B-lineage negative cells in advanced-phase multiple myeloma patients: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Graft versus myeloma may overcome the unfavorable effect of deletion of chromosome 13 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Expression of the c-kit (CD117) molecule in normal and malignant hematopoiesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

A prospective study of CD38/45 flow cytometry and immunofluorescence microscopy to detect blood plasma cells in patients with plasma cell proliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Improvement of clonality detection rate in multiple myeloma using fluorescent IgH PCR with different sets of primers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Automated high resolution PCR fragment analysis for identification of clonally rearranged immunoglobulin heavy chain genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

The detection of contaminating clonal cells in apheresis products is related to response and outcome in multiple myeloma undergoing autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Peripheral blood monoclonal B-cells predict the event free survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Real-Time polymerase chain reaction of immunoglobulin rearrangements for quantitative evaluation of minimal residual disease in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Detection of monoclonality in low-grade B-cell lymphomas using the polymerase chain reaction is dependent on primer selection and lymphoma type

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Qualitative and quantitative polymerase chain reaction detection of the residual myeloma cell contamination after positive selection of CD34+ cells with small- and large-scale Miltenyi cell sorting system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukaemia using real-time polymerase chain reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Application of germline IGH probes in real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Identification of Leptospira biflexa by real-time homogeneous detection of rapid cycle PCR product

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Development and evaluation of a real-time quantitative PCR for the detection of human cytomegalovirus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Molecular detection of clonally rearranged cells in peripheral blood progenitor cell harvests from multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

CD34+ selection of autologous peripheral blood stem cells for transplantation following sequential cycles of high-dose therapy and mobilization in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Linear reduction of clonal cells in stem cell enriched grafts in transplanted multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Real-time polymerase chain reaction in multiple myeloma: quantitative analysis of tumor contamination of stem cell harvests

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Cytomegalovirus colitis after autologous transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Beta2-microglobulin and bone marrow plasma cell involvement predict complete responders among patients undergoing blood cell transplantation for myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

High rate of remission and low rate of disease recurrence in patients with multiple myeloma allografted with PBSC from their HLA-identical sibling donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Sequential analysis of bone marrow and peripheral blood after stem cell transplant for myeloma shows disparate tumor involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Molecular monitoring of the tumor load predicts progressive disease in patients with multiple myeloma after high-dose therapy with autologous peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Infusion of lymphocytes obtained from a donor immunised with the paraprotein idiotype as a treatment in a relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Idiotype immunity (natural and vaccine-induced) in early stage multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: evidence for their capacity to lyse autologous primary tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Optimizing dendritic cell-based immunotherapy in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

Use of quantitative ASO-PCR to predict relapse in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10245330310001638965

10.1080/10245330310001638965

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14965865